



AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.


1. (Original) A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)




wherein R^1 is a C_2 - C_6 alkyl group or the formula (II)




wherein R^2 is a hydrogen atom or an acetyl group and R^3 is a C_1 - C_6 alkyl group, a cycloalkyl group or




wherein R^4 and R^5 are each independently a hydrogen atom or a C_1 - C_6 alkyl group, and in




of the formula (II), R^2 and R^3 may be linked to each other to form




wherein R^6 is a hydrogen atom or a C_1 - C_6 alkyl group;




wherein R^7 and R^8 are each independently a hydrogen atom or a C_1 - C_4 alkyl group,



wherein R^9 and R^{10} are each independently a hydrogen atom or a C_1 - C_4 alkyl group,




wherein R^{11} is a hydrogen atom or a C_1 - C_4 alkyl group; and




wherein R^{12} and R^{13} are each independently a C_1 - C_4 alkyl group or may be linked to each other to form




wherein n is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,





wherein R¹⁴ is a hydrogen atom or a C₁-C₄ alkyl group,



wherein R¹⁵ is a hydrogen atom or an aralkyl group, or




provided that when




and R⁷ should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.


2. (Currently Amended) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a compound of the formula (Ia)




wherein R^{1'} is a C₂-C₆ alkyl group or the formula (II)',




wherein R² is a hydrogen atom or an acetyl group, and R^{3'} is a C₁-C₆ alkyl group or



wherein R⁴ and R⁵ are each independently a hydrogen atom or a C₁-C₆ alkyl group, and in




of the formula (II)', R² and R^{3'} may be linked to each other to form



wherein R⁶ is a hydrogen atom or a C₁-C₆ alkyl group;


R^{9'} and R^{10'} are each independently a C₁-C₄ alkyl group; and



wherein $R^{15'}$ is an aralkyl group, or




3. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)




(I b)

wherein $R^{1''}$ is a C_2 - C_6 alkyl group,



or



wherein R^6 is a hydrogen atom or a C_1 - C_6 alkyl group; and

R^9 and R^{10} are each independently a hydrogen atom or a C_1 - C_4 alkyl group.

4. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. (Previously Presented) The therapeutic agent of claim 1, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

6. (Previously Presented) The therapeutic agent of claim 2, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

7. (Previously Presented) The therapeutic agent of claim 3, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

8. (Previously Presented) The therapeutic agent of claim 4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.